NCT05872724 Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
| NCT ID | NCT05872724 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Suzhou Municipal Hospital |
| Condition | Cervical Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2023-01-16 |
| Primary Completion | 2028-01-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 32 participants in total. It began in 2023-01-16 with a primary completion date of 2028-01-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.
Eligibility Criteria
Inclusion Criteria: 1. Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 \~II A2 cervical cancer. 2. Above the age of 18. 3. General status: ECOG score 0-2. 4. Be able to understand the research scheme, voluntarily participate in the study, and sign the informed consent. 5. Good compliance, able to cooperate with the collection of specimens at each node and provide corresponding clinical information. Exclusion Criteria: 1. Suffering from other malignant tumors. 2. Do not receive the specified treatment or change the treatment regimen before the disease progresses. 3. The study cannot be followed up according to the defined clinical follow-up period. 4. Unable to accept or provide CT or other designated therapeutic evaluation means. 5. Have an autoimmune disease.
Contact & Investigator
jing xue
PRINCIPAL INVESTIGATOR
The Affiliated Suzhou Hospital of Nanjing Medical University
Frequently Asked Questions
Who can join the NCT05872724 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05872724 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05872724 currently recruiting?
Yes, NCT05872724 is actively recruiting participants. Contact the research team at jxue@njmu.edu.cn for enrollment information.
Where is the NCT05872724 trial being conducted?
This trial is being conducted at Suzhou, China.
Who is sponsoring the NCT05872724 clinical trial?
NCT05872724 is sponsored by Suzhou Municipal Hospital. The principal investigator is jing xue at The Affiliated Suzhou Hospital of Nanjing Medical University. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.